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Background: In the single-arm CHRYSALIS study, amivantamab showed durable responses and manageable safety
in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor
(EGFR) exon 20 insertion mutations (ex20ins) who progressed on prior platinum-based chemotherapy. External
controls can provide context for interpreting amivantamab efficacy.
Methods: External controls were selected from three US-based databases (ConcertAI, COTA, and Flatiron). Key
inclusion criteria were diagnosis of EGFR ex20ins advanced NSCLC, prior platinum-based chemotherapy, and
performance status score ≤ 1. Duplicate external controls were identified using a tokenization procedure and
removed, and adjustment for differences in baseline characteristics between amivantamab-treated and external
control cohorts was achieved using propensity score weighting.
Results: Amivantamab-treated and pooled external control cohorts included 81 and 125 patients, respectively.
Baseline characteristics were generally similar across cohorts, except more amivantamab-treated patients were
Asian (56% vs 13%). Most common therapies received by external controls were non-platinum-based chemo
therapy (25.1%), immuno-oncology therapies (24.2%), EGFR tyrosine kinase inhibitors (16.3%), and platinumbased chemotherapy (16.3%). Overall response rate was 40% among amivantamab-treated patients and 16%
among external controls. Amivantamab-treated patients had longer progression-free survival (median 8.3 vs 2.9
months; hazard ratio [HR; 95% CI]: 0.47 [0.34–0.65]), time to next therapy (median 14.8 vs 4.8 months; HR
[95% CI]: 0.40 [0.28–0.57]), and overall survival (median 22.8 vs 12.8 months; HR [95% CI]: 0.49 [0.31–0.77])
than external controls. Results were consistent in sensitivity analyses comparing each external control dataset
against the amivantamab-treated group separately.
Conclusion: Among post-platinum patients with EGFR ex20ins advanced NSCLC, those treated with amivantamab
had improved outcomes, including 10-month longer overall survival, versus external controls.
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1. Introduction
Activating epidermal growth factor receptor (EGFR) mutations are
some of the most common mutations in non-small cell lung cancer
(NSCLC) and represent targetable oncogenic driver events. EGFR exon
20 insertion mutations (ex20ins) are the third most common EGFR
mutations after the common mutations, exon 19 deletions and the exon
21 point mutation L858R.[1] While patients with NSCLC harboring
common EGFR mutations respond well to approved EGFR tyrosine ki
nase inhibitors (TKIs),[2–4] patients with EGFR ex20ins NSCLC are
generally refractory to these agents[1,5–11] owing to altered confor
mation at the kinase active site, which restricts TKI binding.[2,6,11]
Standard first-line treatment for EGFR ex20ins NSCLC is platinum-based
chemotherapy,[12–15] but prognosis remains poor.[2,7,16,17] A high
unmet need exists for safe and effective treatments for patients with
advanced NSCLC harboring EGFR ex20ins because all patients will
eventually progress after platinum-based chemotherapy.[18,19]
Amivantamab (RYBREVANTTM injection for intravenous use; Jans
sen Biotech, Inc.) was the first treatment approved by the Food and Drug
Administration (FDA) for patients with advanced NSCLC harboring
EGFR ex20ins whose disease has progressed on or after platinum-based
chemotherapy.[20] Amivantamab is a fully human, bispecific EGFRdirected and MET receptor-directed antibody that targets activating
and resistance EGFR mutations, as well as MET mutations and amplifi
cations.[19,21–23] Amivantamab is hypothesized to not be affected by
mutations that affect affinity in the EGFR TKI binding pocket because it
binds to the extracellular domains of EGFR and MET.[19] As a result,
amivantamab is able to overcome the inherent resistance of EGFR
ex20ins NSCLC to targeted therapies. Once bound to its target, the antitumor activity of amivantamab includes inducing trogocytosis from
macrophages, eliciting antibody-dependent cellular cytotoxicity from
natural killer cells, and causing receptor-antibody complex endocytosis
and removal via lysosomal trafficking.[19,22–24]
In CHRYSALIS (NCT02609776)—a first-in-human, open-label, doseescalation, phase 1 study—the safety, pharmacokinetics, and efficacy of
amivantamab is being evaluated in adults with advanced NSCLC as
monotherapy and in combination with the EGFR TKI lazertinib, as well
as with chemotherapy.[25–28] An expansion cohort in CHRYSALIS
included patients with EGFR ex20ins advanced NSCLC who
received amivantamab at the recommended phase 2 dose (RP2D;
1050 mg, < 80 kg; 1400 mg, ≥ 80 kg). Among 81 patients who
experienced disease progression after platinum-based chemotherapy,
amivantamab showed durable responses and manageable safety.[28]
Confirmed overall response rate (ORR) per Response Evaluation
Criteria in Solid Tumors (RECIST) v1.1 was 40% with a median dura
tion of response (DOR) of 11.1 months; median progression-free sur
vival (PFS) was 8.3 months; and median overall survival (OS) was 22.8
months.
Because CHRYSALIS is a non-randomized, single-arm study, external
controls can add valuable context in interpreting efficacy findings for
amivantamab and appreciating unmet needs with available real-world
therapies. We conducted a protocol-driven, treatment comparison of
amivantamab and real-world therapies in patients with advanced
NSCLC harboring EGFR ex20ins in whom platinum-based chemotherapy
failed using data from the subset of patients from CHRYSALIS and
external controls from three US-based, real-world data sources.
To view a summary of the study presented by Dr Anna Minchom

Video Summary.

2. Methods
The primary objective of this study was to evaluate the effectiveness
of amivantamab versus physicians’ choice of anticancer treatment in
real-world settings among patients with advanced NSCLC harboring
EGFR ex20ins in whom platinum-based chemotherapy failed. A sec
ondary objective was to describe real-world treatment patterns for these
patients.
2.1. Patients
The CHRYSALIS (amivantamab-treated) cohort included a subset of
patients from CHRYSALIS (n = 81) who were ≥ 18 years old with EGFR
ex20ins advanced NSCLC, disease progression on or after platinumbased chemotherapy (receipt of adjuvant platinum-based chemo
therapy must have been ≤ 12 months from metastatic diagnosis to be
included), Eastern Cooperative Oncology Group Performance Status
(ECOG PS) score of ≤ 1, no prior treatment with a TKI with known ac
tivity against EGFR ex20ins NSCLC, and no other malignancy within
three years of screening, as well as adequate organ and bone marrow
function; no uncontrolled comorbidity or comorbid leptomeningeal
disease, HIV, hepatitis B or C, and/or interstitial lung disease; no un
treated brain metastases; and no clinically significant cardiovascular
disease. The CHRYSALIS study was approved by an Independent Ethics
Committee and carried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki). All patients pro
vided written informed consent.
The external control cohort comprised patients in real-world data
sources who met clinically relevant eligibility criteria for CHRYSALIS
(Table 1), including age ≥ 18 years at advanced NSCLC diagnosis, an
ECOG PS score ≤ 1, no other malignancy within the prior three years
(with exceptions consistent with those in CHRYSALIS), and evidence of
prior exposure to platinum-based chemotherapy after metastatic NSCLC
diagnosis or in the 12 months before metastatic NSCLC diagnosis.
Lines(s) of therapy (LOT) from external controls with missing ECOG PS
scores were excluded in the primary (pooled) analyses but were included
in some of the sensitivity analyses.
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censored on the date of the last disease assessment before the start of
subsequent therapy and at the start of subsequent therapy, respectively.
TTNT, censored at loss to follow-up, was compared to rwTTNT in the
real-world data sources. Death was treated as an event for purposes of
calculating TTNT.
OS was defined as the interval between the index date and the date of
death for the amivantamab-treated cohort. For patients who were alive,
or for whom vital status was unknown, OS was censored on the date the
patient was last known to be alive. rwOS was based on information in
the EHR and external sources (eg, social security records and obituaries),
and was censored on the last-known-alive date.
Because CHRYSALIS included patients at any time after receipt of
platinum-based chemotherapy, an approach recommended by Hernan
et al.[29,30] was used to identify suitable external controls. This
approach accepts all qualifying LOT; therefore, a given external control
could have been included in the analysis multiple times, once each time
they qualified based on inclusion criteria. The index date was considered
the start of each LOT. Appropriate adjustments[31] were made for
correlated data within patients.

2.2. Real-world data sources
Custom-curated, real-world data abstracting clinically relevant
measures (eg, brain metastases, real-world tumor response, and realworld PFS [rwPFS]) from 2011 to 2020 were obtained from three deidentified, retrospective databases (ConcertAI [ConcertAI], COTA
[COTA Healthcare], and Flatiron [Flatiron Health Inc.]) that included
patients in the United States with NSCLC and confirmed EGFR ex20ins
(Supplementary Table 1). The ConcertAI and Flatiron Health Spotlight
datasets each contained aggregate data for patients with EGFR ex20ins
advanced NSCLC from US cancer clinics, primarily in the community
oncology setting. The datasets included electronic health record (EHR)
data derived from structured fields, and data abstracted from physi
cians’ notes and other documents (eg, biomarker reports). The COTA
dataset contained data for patients with confirmed EGFR ex20ins NSCLC
from five US healthcare sites (79% academic medical centers; 21%
community oncology setting).
2.3. Efficacy assessments
Efficacy endpoints were ORR, PFS, time to next treatment (TTNT),
and OS. Because follow-up and surveillance for events are different in
clinical trials than in real-world settings, endpoints for the external
control cohort were defined as rwORR, rwPFS, rwTTNT, and rwOS.
For the amivantamab-treated cohort, ORR was defined as the per
centage of patients who achieved a confirmed best overall response of
complete response (CR) or partial response (PR) based on RECIST v1.1
criteria and was determined by blinded independent central review.
rwORR was based on human abstraction of physician evaluation of
tumor scans in the EHR, not on RECIST criteria, and confirmation of
response was required. A confirmed best real-world overall response of
CR or PR in a particular line setting required a scan associated with a
physician-noted CR or PR during that LOT, as well as a subsequent scan
during the same line setting associated with a physician notation of
stable disease (SD), PR, or CR without an intervening scan associated
with a physician-noted response of progressive disease (PD). If the
intervening scan was missing, the next non-missing scan was used. To
avoid underestimation of rwORR, LOT without available responses were
removed from the analyses.
For the amivantamab-treated cohort, PFS was defined as the interval
between the index date (date of first amivantamab dose) and the date of
PD (based on RECIST v1.1) or death, whichever occurred first. Patients
with no post-baseline assessments were censored on the index date.
rwPFS was based on human abstraction of physician evaluation of tumor
progression, not on RECIST criteria (PD within 14 days of the index date
was not included). Amivantamab-treated patients and external controls
who started a subsequent anticancer therapy in the absence of PD were

2.4. Analyses
Analyses were conducted using individual, patient-level data. The
amivantamab-treated efficacy dataset included patients from CHRYS
ALIS with EGFR ex20ins advanced NSCLC who received prior platinumbased chemotherapy, received the RP2D of amivantamab on or before
February 5, 2020, and had ≥ 2 post-baseline disease efficacy assess
ments, or discontinued treatment for any reason, or had PD or death
before the second post-baseline disease assessment. The external control
efficacy dataset included patients in the real-world data sources who
satisfied key inclusion-exclusion criteria for the CHRYSALIS study.
Propensity score weighting (average treatment effects on the treated)
[32] was used to weight external controls in each real-world dataset to
the distribution of baseline covariates in CHRYSALIS (eg, age, brain
metastases, number of prior LOT in the metastatic setting, and [in
pooled analyses] baseline ECOG PS score). Standardized mean differ
ences (SMDs) between external controls and amivantamab-treated pa
tients were plotted on a love plot before and after baseline covariate
adjustment. An absolute SMD of < 10% after adjustment for each
baseline covariate in the propensity score model was considered to
indicate good balance.[33]
Treatment effects were compared between amivantamab-treated
patients and external controls, separately as individual datasets and as
a pooled dataset after de-duplication. De-duplication using a tokeniza
tion procedure allowed for Health Insurance Portability and Account
ability Act of 1996-compliant identification of duplicate patients across
the three real-world datasets. Patients in the Flatiron database were

Table 1
Real-world Data Source Disposition After Applying Key CHRYSALIS Inclusion Criteria and After De-duplication.
Pooled
Key CHRYSALIS
criteria

ConcertAI

COTA

Flatiron

n

Reduction

n

Reduction

n

Reduction

n

Reduction

Received from vendor
Advancved NSCLC and EGFR ex20ins
≥ 18 years at advanced NSCLC diagnosis
Platinum-based chemotherapy after metastatic diagnosis or in
12 months prior
≥ 1 LOT after platinum-based chemotherapy
ECOG PS score of 0 or 1 (or missing) at start of qualifying therapy
No record of other malignancy in 3 years before start of qualifying
therapy

391
371
371
282

–
5.1%
0.0%
24%

99
96
96
75

–
3.0%
0.0%
21.9%

92
75
75
63

–
18.5%
0.0%
16.0%

200
200
200
144

–
0.0%
0.0%
28.0%

193
180
174

31.6%
6.7%
3.3%

54
50
48

28.0%
7.4%
4.0%

42
42
42

33.3%
0.0%
0.0%

97
88
84

32.6%
9.3%
4.5%

After de-duplication

125a

28.2%

35

27.1%

39

7.1%

84

0.0%

ECOG PS, Eastern Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion mutations; LOT, line(s) of
therapy; NSCLC, non-small cell lung cancer
a
Excludes LOT from patients with missing ECOG PS scores.
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removed from ConcertAI and COTA databases, and patients in the
ConcertAI database were removed from the COTA database. LOT from
patients with missing ECOG PS scores were excluded in analyses of realworld pooled data. Study power was not formally assessed because
sample sizes were fixed according to the number of patients in the
amivantamab-treated and external control cohorts meeting key inclu
sion criteria.
External controls who qualified for inclusion and had ≥ 1 LOT after
platinum-based chemotherapy were included in analyses once for each
qualifying LOT. Appropriate adjustments were made to confidence in
tervals (CIs) to account for correlation of outcomes within patients using
the grouped jackknife for time-to-event outcomes[31] and generalized
estimating equations for binary outcomes.[34]
For ORR, adjusted percentages and odds ratios (ORs) with 95% CIs
were calculated using weighted logistic regression with generalized
estimating equations. The robust variance estimator was used to account
for average treatment effects on the treated and overlapping weights.
Time-to-event assessments (OS, PFS, and TTNT) were calculated using
weighted Kaplan-Meier survival function estimation. Median survival
times with 95% CIs, as well as hazard ratios (HRs) and 95% CIs, were
calculated using weighted Cox proportional hazards regression. Left
truncation adjustment was applied for OS analyses to account for bias
arising from the inclusion of LOT starting before EGFR ex20ins results
were available.[35] The database cut-off for the amivantamab group
was October 8, 2020. However, to allow more time for OS maturity, the

OS analysis was refreshed using an April 19, 2021 snapshot.
2.5. Sensitivity analyses
Sensitivity analyses were conducted to evaluate the impact of certain
criteria and analytic methods on differences in outcomes (ORR, PFS,
TTNT, and OS) between groups. Analyses were conducted (1) with and
without LOT from patients with missing ECOG PS scores; (2) only
including external controls in their second LOT (if that was a qualifying
LOT)—to be conservative, where external controls had the longest
possible survival, and external controls were each included only once in
the analyses; (3) for OS, stratified by the number of prior LOT in the
metastatic setting; (4) including only LOT from external controls who
started ≥ 30 days before EGFR ex20ins results were first available, and
no left truncation adjustment was applied—this landmark analysis
strategy is robust against violations of the assumption required for the
left truncation adjustment (ie, the “independent delayed entry”
assumption that survival does not depend on when a patient is
sequenced); and (5) for PFS and OS, taking timing of treatment (received
on or before December 31, 2015 vs on or after January 1, 2016) of
external controls into consideration given treatment options changed
during the 10-year, real-world data collection period.

Table 2
Baseline Demographics and Clinical Characteristics (All Qualifying LOT for Each Patient [Without Weighting]).
CHRYSALIS
n = 81
81 LOT

Real-world pooled dataseta
n = 125
227 LOT

ConcertAI
n = 48
102 LOT

COTA
n = 42
98 LOT

Flatiron
n = 84
168 LOT

Age, median [min; max]

62.0 [42.0;84.0]

62.0 [31.0;84.0]

61.5 [36.0;84.0]

61.0 [31.0;78.0]

65.0 [40.0;82.0]

Sex, n (%)
Female
Male

48 (59.3)
33 (40.7)

137 (60.4)
90 (39.6)

64 (62.7)
38 (37.3)

59 (60.2)
39 (39.8)

90 (53.6)
78 (46.4)

Race, n (%)
Asian
Black or African American
White
Other
Missing

40 (55.6)
2 (2.8)
30 (41.7)
0 (0.0)
9 (11.1)

27 (13.0)
11 (5.3)
140 (67.3)
30 (14.4)
19 (8.4)

0 (0.0)
11 (12.2)
62 (68.9)
17 (18.9)
12 (11.8)

7 (7.5)
8 (8.5)
75 (79.8)
4 (4.26)
4 (4.1)

20 (12.8)
5 (3.2)
100 (64.1)
31 (19.9)
40 (23.8)

Smoking history, n (%)
No
Yes
Missing

43 (53.1)
38 (46.9)
0 (0.00)

133 (58.8)
93 (41.2)
1 (0.44)

62 (62.0)
38 (38.0)
2 (1.96)

53 (54.1)
45 (45.9)
0 (0.0)

89 (53.0)
79 (47.0)
0 (0.0)

ECOG PS score, n (%)
0
1
2b
Missing

26 (32.1)
54 (66.7)
1 (1.2)
0 (0.0)

69 (30.4)
158 (69.6)
0 (0.0)
0 (0.0)

35 (43.2)
46 (56.8)
0 (0.0)
21 (20.6)

6 (7.9)
70 (92.1)
0 (0.0)
22 (22.4)

35 (33.3)
70 (66.7)
0 (0.0)
63 (37.5)

Brain metastasis at baseline, n (%)
No
Yes

63 (77.8)
18 (22.2)

137 (60.4)
90 (39.6)

64 (62.7)
38 (37.3)

57 (58.2)
41 (41.8)

108 (64.3)
60 (35.7)

Prior lines in metastatic setting,c n (%)
0–1
2
3+
Time from advanced diagnosis to LOT (months), median [min; max]

29 (35.8)
23 (28.4)
29 (35.8)
14.1 [0.66;116]

100 (44.1)
63 (27.8)
64 (28.2)
14.8 [0.23;85.6]

47 (46.1)
25 (24.5)
30 (29.4)
13.5 [0.10;55.2]

38 (38.8)
32 (32.7)
28 (28.6)
15.3 [0.69;85.6]

77 (45.8)
42 (25.0)
49 (29.2)
14.6 [0.39;54.5]

ECOG PS, Eastern Cooperative Oncology Group Performance Status; LOT, line(s) of therapy
a
After de-duplication and exclusion of patient LOT with missing ECOG PS scores.
b
One enrolled patient was reclassified as having an ECOG PS score 2 rather than 1.
c
Does not include neo-adjuvant/adjuvant platinum-based chemotherapy (or any other therapy) before date of metastatic non-small cell lung cancer diagnosis.
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2.6. Real-world treatment patterns

Table 3
Real-world Treatment Patterns for EGFR ex20ins Advanced NSCLC by LOT After
Platinum-based Chemotherapy (Real-world Pooled Dataset).

Treatments received in real-world settings were categorized as nonplatinum chemotherapies (eg, paclitaxel, docetaxel, gemcitabine,
pemetrexed, vinorelbine, and mitomycin); immuno-oncology (IO)
therapies (eg, nivolumab, pembrolizumab, atezolizumab, durvalumab)
with or without vascular endothelial growth factor inhibitors (VEGFi);
platinum-containing regimens, which included platinum alone, plat
inum and a TKI, platinum and an IO therapy, platinum and an IO therapy
and a VEGFi, and platinum and a VEGFi; TKI (eg, afatinib, gefitinib,
erlotinib and osimertinib) with or without VEGFi; VEGFi alone; and
other (clinical study drugs, anaplastic lymphoma kinase [ALK] in
hibitors, multi-kinase inhibitors, anti-EGFR monoclonal antibodies,
mammalian target of rapamycin (mTOR) inhibitors, and estrogen
modulators). Analyses were conducted after de-duplication and exclu
sion of LOT from patients with missing ECOG PS scores.

After platinum-based chemotherapy
Line 1

Line 2

Line ≥ 3

Unique patients, na
Lines of therapy

125
125

53
53

27
49f

Real-world treatments, n (%)
IO
Platinum-containing regimenb,c
TKI
Non-platinum chemod
Otherse
VEGFi alone

36
23
21
19
15
11

12 (22.6)
9 (17.0)
8 (15.1)
17 (32.1)
1 (1.9)
6 (11.3)

7 (14.3)
5 (10.2)
8 (16.3)
21 (42.9)
5 (10.2)
3 (6.1)

(28.8)
(18.4)
(16.8)
(15.2)
(12.0)
(8.8)

ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology
Group Performance Status; ex20ins, exon 20 insertion mutations; IO, immunooncology; LOT, line(s) of therapy; mTOR, mammalian target of rapamycin;
TKI, tyrosine kinase inhibitor; VEGFi, vascular endothelial growth factor
inhibitor
a
After de-duplication and exclusion of patient LOT with missing ECOG PS
scores.
b
Includes platinum alone, platinum plus TKI, platinum plus IO, platinum plus
IO plus VEGFi plus platinum plus VEGFi.
c
Reflects either re-treatment of a patient with platinum after an intervening
LOT or a combination of platinum with a different agent(s) that triggered a LOT
change.
d
Includes paclitaxel, docetaxel, gemcitabine, pemetrexed, vinorelbine, eto
poside, and mitomycin.
e
Includes clinical study drugs, ALK inhibitors, multi-kinase inhibitors, antiEGFR monoclonal antibodies, mTOR inhibitors, and estrogen modulators.
f
Includes unique patients who received multiple LOT.

3. Results
3.1. Patients
The amivantamab-treated efficacy analysis set included 81 patients
treated with amivantamab at the RP2D (81 LOT; Table 2). The external
control efficacy analysis set included 174 patients (368 LOT): 48 from
ConcertAI (102 LOT), 42 from COTA (98 LOT), and 84 from Flatiron
(168 LOT). The external control pooled analysis set, after de-duplication
and exclusion of patient LOT with missing ECOG PS scores, included 125
unique patients (227 LOT; Table 1).
Before propensity weighting, baseline characteristics were generally
comparable across datasets, except for more patients of Asian descent in
the amivantamab-treated cohort (55.6%) than among the external
control cohorts (pooled dataset: 13.0%; Table 2). Among amivantamabtreated and pooled external control cohorts, median age was 62 years
(range: 42–84 and 31–84 years, respectively), approximately 60% of
patients in each cohort were female, and less than half were smokers
(46.9% and 41.2%, respectively). Most patients had an ECOG PS score

of ≤ 1 (98.8% and 100.0%, respectively) and had adenocarcinoma
histology (95.1% and 96.0%, respectively). Fewer amivantamab-treated
patients than external controls had brain metastases at baseline (22.2%
vs 39.6%, respectively), as expected given the inclusion criteria in

Fig. 1. Love plot displaying baseline covariate balance before and after adjustment (external controls [pooled dataset] vs amivantamab-treated pa
tients). A good balance was considered an absolute standardized mean difference of < 10% after adjustment for each baseline covariate included in the propensity
score model.[33] ECOG PS, Eastern Cooperative Oncology Group Performance Status; LOT, line(s) of therapy.
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CHRYSALIS. Compared to first qualifying LOT for external controls,
more amivantamab-treated patients had ≥ 2 prior LOT in the metastatic
setting (55.9% vs 64.2%, respectively), and the median time from
advanced diagnosis to treatment was 14.1 [0.66;116] for amivantamabtreated patients versus 14.8 [0.23;85.6] for external controls.
After propensity weighting, good balance of covariates between the
amivantamab-treated and external control cohorts was achieved. For
example, absolute SMDs of < 10% were achieved for external controls
(pooled dataset) versus amivantamab-treated patients after adjustment
for each baseline covariate included in the model (Fig. 1).

population.[1,6] Of note, however, Asian patients were more prevalent
in the amivantamab-treated cohort than in the US-based, real-world
datasets because CHRYSALIS initiated in Korea before expanding to the
United States and other countries.[28] Still, the efficacy of chemo
therapy or immune checkpoint inhibitors has never been reported as
being different across ethnicities. Clinical outcomes were better with
amivantamab than with real-world therapies in patients with EGFR
ex20ins advanced NSCLC post platinum-based chemotherapy.
Amivantamab-treated patients had a 10-month longer median OS (me
dian: 22.8 vs 12.8 months [data cut-off April 19, 2021]), as well as
improved PFS (median 8.3 vs 2.9 months), TTNT (median 14.8 vs 4.8
months), and ORR (median 40% vs 16%). The poor performance of the
external controls substantiates the ineffectiveness of currently available
real-world treatments and highlights the potential treatment advantage
with amivantamab in this patient population.
In the present study, the real-world treatment pattern of patients
with advanced NSCLC harboring EGFR ex20ins confirms the limited
options after failure of platinum-based chemotherapy, with no clear
standard in the post-platinum setting.[14] After progression on
platinum-based chemotherapy, most commonly used first LOT were IO
therapies (28.8%), followed by platinum-based chemotherapy (18.4%)
and TKIs (16.8%), despite established poor response rates to immune
checkpoint inhibitors and EGFR TKIs among patients with EGFR ex20ins
NSCLC.[38] As the external controls used in this study comprised pa
tients from three independent real-world datasets, the findings corrob
orate and strengthen prior reports on the lack of and ineffectiveness of
real-world treatments using just the Flatiron database.[14,37] Mean
while, findings from the external control cohort show that patients with
EGFR ex20ins may actually receive multiple lines of therapy, high
lighting the need to optimize treatment sequences.
The trajectory of treatment options for patients with EGFR ex20ins
NSCLC who progressed on or after platinum-based chemotherapy likely
will change as the FDA-approved therapies such as amivantamab and
mobocertinib become more widely prescribed in real-world clinical
practice. Availability of these therapies and potentially other investi
gational treatments, such as the EGFR ex20ins-specific TKIs TAS6417/
CLN-081 and DZD9008, may lead to modifications in treatment
sequencing protocols and improvements in clinical outcomes.
A strength of this protocol-driven study was comparison of individ
ual, patient-level data from three disease-specific, real-world data
sources with clinical trial data. The real-world datasets were curated to
provide additional key prognostic information (eg, brain metastases,
progression events) and outcomes that are not typically available in offthe-shelf datasets. Another strength of the study was the conduct of
sensitivity analyses to substantiate the robustness of the results. Con
sistency of results across the three real-world datasets, among the four
efficacy outcomes, and across sensitivity analyses raises confidence in
the robustness of our findings.
Limitations of this study include the potential that real-world data
sets lacked consistency in assessments such as physician assessment of
performance status and physician assessment of radiological response in
comparison to protocol-driven trial assessments, including RECIST
radiological assessment. In addition, comparisons were between ami
vantamab treatment in a clinical trial setting and a range of therapies
selected by physicians in real-world practice based on patient charac
teristics. Supportive care in real-world settings was also likely different
from that received by clinical trial patients. Further, findings from prior
studies indicate that patients in clinical trials may be healthier than the
general population.[39,40] Finally, formal statistical comparisons
across cohorts were not carried out because this was not a randomized
study; thus, the potential for unmeasured confounding cannot be ruled
out.
In conclusion, patients with advanced NSCLC harboring EGFR
ex20ins whose disease progressed on or after platinum-based chemo
therapy have poor prognoses and are in need of more effective therapies.
Amivantamab improved ORR, OS, PFS, and TTNT compared to real-

3.2. Real-world therapies
Most common therapies received by external controls across their
qualifying LOT in the post-platinum setting were non-platinum-based
chemotherapy (25.1%), IO therapies with or without VEGFi (24.2%),
platinum-containing regimens (16.3%), and TKIs with or without VEGFi
(16.3%). Most common therapies received by ECs in their first LOT after
platinum-based chemotherapy were IO therapies with or without VEGFi
(28.8%), platinum-containing regimens (18.4%), and TKIs with or
without VEGFi (16.8%; Table 3).
3.3. Treatment outcomes
Confirmed ORR was 40% (95% CI: 29.5%, 50.5%) among
amivantamab-treated patients and 16% (95% CI: 11.2%, 22.0%) for the
external control pooled dataset (OR [95% CI]: 3.47 [1.90, 6.33]). ORRs
were 13% (95% CI: 6.4%, 25.1%; OR: 4.32 [1.73, 10.77]) for external
controls in ConcertAI, 18% (95% CI: 11.1%, 27.6%; OR: 3.00 [1.46,
6.13]) in COTA, and 15% (95% CI: 10.3%, 21.8%; OR: 3.64 [1.94, 6.83])
in Flatiron (Supplementary Fig. 1).
Amivantamab-treated patients had longer PFS (HR [95% CI]: 0.47
[0.34, 0.65]; median: 8.3 vs 2.9 months) and longer TTNT (HR [95%
CI]: 0.40 [0.28, 0.57]; median: 14.8 vs 4.8 months) than external con
trols (pooled dataset; Fig. 2A and B). Furthermore, amivantamab-treated
patients had longer OS (HR [95% CI]: 0.49 [0.31, 0.77]; median: 22.8 vs
12.8 months [data cut-off April 19, 2021]) than external controls
(pooled dataset; Fig. 2C). Findings for each outcome were consistent
across real-world datasets (Supplementary Fig. 2).
Results of sensitivity analyses for ORR, PFS, TTNT, and OS were
consistent with those from the main analyses (Supplementary Figs. 3–7).
4. Discussion
With standard treatment options, patients with advanced NSCLC
harboring EGFR ex20ins have poor prognoses, with a median OS of
approximately 16 months.[14,36] The standard of care for these pa
tients is platinum-based chemotherapy; however, all patients will
eventually experience disease progression, with limited treatment op
tions in subsequent LOT.[2,7,11,36] In a real-world analysis, median OS
was 12.5 months and median PFS was 3.5 months in the relapsed setting,
[37] emphasizing the high unmet need associated with EGFR ex20ins
advanced NSCLC.
Amivantamab, the first treatment approved by the FDA for patients
with advanced NSCLC harboring EGFR ex20ins whose disease pro
gressed on or after platinum-based chemotherapy,[20] is a new targeted
therapy in the treatment armamentarium for these patients. In this
protocol-driven analysis using three US-based, real-world datasets,
treatment outcomes of amivantamab were compared with those of realworld therapies among patients with EGFR ex20ins advanced NSCLC in
whom platinum-based chemotherapy failed. Demographics and baseline
characteristics of amivantamab- and real world-treated patients were
well balanced across datasets and consistent with known traits of pa
tients with advanced NSCLC harboring EGFR ex20ins; most patients had
tumors of adenocarcinoma histology and with overrepresentation of
females and non-smokers relative to the broader advanced NSCLC
79

A. Minchom et al.

Lung Cancer 168 (2022) 74–82

Fig. 2. Kaplan-Meier Curves (after weighting) for
amivantamab-treated patients (CHRYSALIS) and
external controls* (pooled dataset). (A)
Progression-free survival, (B) Time to next
treatment, and (C) Overall survival.y *Excludes
LOT from patients with missing ECOG PS scores.
†
Left truncation adjustment was applied to account
for bias arising from inclusion of patients whose
EGFR ex20ins results were only available after the
start of a qualifying LOT. Data cut-off was October 8,
2020 for analyses of progression-free survival and
time to next treatment and April 19, 2021 for anal
ysis of overall survival. CI, confidence interval;
EGFR, epidermal growth factor receptor; ex20ins,
exon 20 insertion mutations; HR, hazard ratio; LOT,
line(s) of therapy; RWD, real-world data; RWE, realworld evidence.
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Overall survival
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world therapies.
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